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Abstract: Coronary heart disease is the major cause of morbidity and mortality throughout the 
world, and is responsible for approximately one of every six deaths in the US. Angina pectoris 
is a clinical syndrome characterized by discomfort, typically in the chest, neck, chin, or left arm, 
induced by physical exertion, emotional stress, or cold, and relieved by rest or nitroglycerin. 
The main goals of treatment of stable angina pectoris are to improve quality of life by reducing 
the severity and/or frequency of symptoms, to increase functional capacity, and to improve 
prognosis. Ranolazine is a recently developed antianginal with unique methods of action. In 
this paper, we review the pharmacology of ranolazine, clinical trials supporting its approval 
for clinical use, and studies of its quality of life benefits. We conclude that ranolazine has been 
shown to be a reasonable and safe option for patients who have refractory ischemic symptoms 
despite the use of standard medications (for example, nitrates, beta-adrenergic receptor antago-
nists, and calcium channel antagonists) for treatment of anginal symptoms, and also provides 
a modestly improved quality of life.
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Introduction
Coronary heart disease is the major cause of morbidity and mortality throughout 
the world.1 About 16.3 million people in the US have coronary heart disease and an 
estimated 8.9 million people have chronic stable angina.2,3 Coronary heart disease is 
responsible for approximately one of every six deaths in the US,3 and based on data 
from 2007, the estimated direct and indirect cost of coronary heart disease in the US 
annually exceeds $177.5 billion.3,4
Angina pectoris is a clinical syndrome characterized by discomfort, typically in 
the chest, neck, chin, or left arm, induced by physical exertion, emotional stress, or 
cold, and is relieved by rest or nitroglycerin.2 It is present symptomatically in only 
18% of coronary artery disease.3 Chronic stable angina is usually caused by partial but 
flow-limiting obstruction of at least one of the major coronary arteries or its branches 
by atheromatous plaque, resulting in myocardial ischemia as a result of a mismatch 
between myocardial oxygen demand and supply.5
The general management of chronic stable angina is directed at medical therapy to 
reduce coronary heart disease progression, as well as therapies and lifestyle modifica-
tion to control or eliminate coronary heart disease risk factors (smoking, high blood 
pressure, diabetes mellitus, hyperlipidemia, physical inactivity, weight management, 
and influenza vaccination).2,6Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The treatment of chronic stable angina aims to increase 
myocardial oxygen supply by vasodilation (eg, nitrates, 
  calcium channel blockers), to reduce coronary artery obstruc-
tion (eg, percutaneous coronary intervention or coronary 
artery bypass grafting), and to decrease myocardial oxygen 
demand (eg, beta-adrenergic receptor blockers, calcium chan-
nel blockers).7–9 The goals of such treatment are to improve 
quality of life by reducing the severity and/or frequency of 
symptoms, to increase functional capacity, and to improve 
the prognosis of the patient, by preventing myocardial infarc-
tion and death.
Medical management, aimed at preventing future clinical 
events, is pivotal in all patients with coronary artery disease 
and includes antiplatelet agents (aspirin and clopidogrel), 
beta-adrenergic receptor blockers, angiotensin-converting 
enzyme inhibitors and/or renin-angiotensin-aldosterone 
system blockers, nitrates, calcium channel antagonists, and 
lipid-lowering agents.6,10 In addition, specific treatment may 
be needed to control angina symptoms. Antianginal drug 
treatment should be tailored to the needs of each patient and 
should be monitored individually. Short-acting nitrate therapy 
should be prescribed for all patients for immediate relief of 
acute symptoms as tolerated. Although different drugs have 
been shown to have additive antianginal effects in clinical tri-
als, this may not necessarily be so in an individual patient.
Coronary revascularization (percutaneous coronary 
intervention or coronary artery bypass grafting) is also an 
option for the relief of angina when medical therapy fails,11 
but as demonstrated in the COURAGE trial, when used on 
the background of optimal medical therapy, does not reduce 
death or myocardial infarction compared with optimal 
medical therapy alone.6,10,12 Still, despite management with 
existing medical and revascularization options, millions of 
patients experience acute and chronic anginal symptoms. 
It is known, for example, that more than 25% of patients 
after revascularization, even if on optimal medical therapy, 
can develop a new ischemic symptom in five years.7,13 This 
observation underpins the ongoing need to develop new anti-
anginal drugs. Most recently, ranolazine has been developed 
as one such option.
Ranolazine
Pharmacology and antianginal effects
Ranolazine is a novel antianginal agent, with a different 
mechanism of action from the common agents, that reduces 
ischemia in patients with chronic angina.14,15 Although it 
has weak alpha-adrenergic and beta-adrenergic antagonist 
properties, under normal physiological conditions, these 
properties are dominated by its effects on the autonomic 
nervous system.16–18 Therefore, it is not classified as a beta-
adrenergic receptor blocker, calcium channel antagonist, or 
a vasodilator.19 Ranolazine preferentially blocks the cardiac 
late sodium current at concentrations that do not inhibit the 
peak transient current.20 This novel mechanism of action is 
postulated to reduce angina symptoms by avoiding ischemia-
induced sodium and overload in cardiac myocytes during 
ischemia.7,15,21 Ranolazine is also believed to inhibit par-
tially fatty acid oxidation,22 resulting in a shift in substrate 
metabolism towards glucose during ischemia that may also 
contribute to reduction in angina symptoms.
Regardless of the postulated mechanism, based on its abil-
ity to improve exercise performance, increase the time until 
angina recurs, and reduce angina frequency (alone and on 
top of other standard antianginal agents),9,19,22 ranolazine was 
approved by the US Food and Drug Administration in 200623 
for use in patients with chronic stable angina. Importantly, in 
the trials that led to its approval, ranolazine did not appear to 
affect heart rate or blood pressure, and was generally well 
tolerated. The primary safety concern was prolongation of 
the rate-corrected QT interval (QTc) with ranolazine treat-
ment, without clinical cases of torsades de pointes. This 
safety signal was later addressed in the MERLIN-TIMI 
(Metabolic Efficiency with Ranolazine for Less Ischemia 
in Non-ST Elevation Acute Coronary Syndromes) 36 trial 
discussed later.8
Metabolism
Several routes for elimination of ranolazine have been 
  identified. It is metabolized both in the liver through the cyto-
chrome P450 3A enzyme pathway and in the intestine,21,24,25 
and more than 70% of the drug is excreted as metabolites in 
the urine.21 Clearance of ranolazine is reduced by renal insuf-
ficiency and moderate hepatic impairment; therefore, careful 
dose adjustment is required in patients with mild to moder-
ate renal insufficiency or hepatic impairment. Ranolazine is 
contraindicated in patients with severe renal insufficiency or 
moderate to severe hepatic impairment.15,26
Many drugs are also known to interact with its metabo-
lism and affect its clearance, increasing ranolazine plasma 
concentrations, including ketoconazole, diltiazem, and 
verapamil. Concomitant use of ranolazine can increase the 
plasma concentration of simvastatin and digoxin.15,21
Randomized clinical trials
In the last decade, several randomized clinical trials have 
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  investigating the efficacy of ranolazine to improve angina 
relief and exercise performance and duration. MARISA 
(Monotherapy Assessment of Ranolazine In Stable Angina), 
a double blind, placebo-controlled study, investigated the 
effect of three different doses of ranolazine (500, 1000 or 
1500 mg, each administered twice daily) on total exercise 
duration in 191 patients with angina-limited exercise. All 
doses of ranolazine were well tolerated and effective in 
reducing angina frequency and increasing exercise duration 
(by 94, 103 and 116 seconds, P , 0.005 compared with 
placebo) when used as monotherapy.19
The ERICA (Antianginal Efficacy of Ranolazine When 
Added to Treatment With Amlodipine) trial addressed whether 
ranolazine decreased the symptoms of angina in stable coro-
nary patients who had persistent symptoms even with the use 
of maximum recommended doses of amlodipine. The popula-
tion in this study consisted of 565 stable patients with known 
coronary disease taking maximal amlodipine doses and having 
three or more anginal attacks per week. Patients were random-
ized to ranolazine 1000 mg versus   placebo twice daily for six 
weeks. The results showed that ranolazine in combination with 
amlodipine reduced the frequency of angina compared with 
amlodipine alone (mean anginal attacks per week 2.88 versus 
3.31, P = 0.028; average weekly   nitroglycerin consumption 
2.03 versus 2.68, P = 0.014).9
CARISA (Combination Assessment of Ranolazine In 
  Stable Angina), a randomized three-group parallel, double-
blind placebo-controlled study, had the primary aim of compar-
ing the effects of ranolazine 750 mg or 1000 mg versus placebo 
on treadmill exercise duration in 823 patients with persistent 
symptoms of chronic angina despite use of maximum doses 
of atenolol, amlodipine, or diltiazem. This trial demonstrated 
the ability of ranolazine to improve exercise capacity (exercise 
duration increased by 115.6 seconds from baseline in both 
ranolazine groups versus 91.7 seconds in the placebo group, 
P = 0.01) and increase time to the onset of angina on the back 
drop of these standard antianginal medications.22
The most recent investigation, the MERLIN-TIMI 36 
trial, evaluated the efficacy and safety of ranolazine in 6560 
patients with non-ST segment elevation acute coronary 
syndromes. Although the primary endpoint of the study 
was not met (reduction of a composite of cardiovascular 
death, myocardial infarction, and recurrent ischemia in the 
ranolazine arm compared with standard treatment) the inci-
dence of recurrent ischemia was significantly lower in the 
ranolazine group compared with standard treatment (13.9% 
versus 16.1%; hazards ratio 0.8, 95% confidence interval 
0.76–0.99).7
Overall, ranolazine has been well tolerated in the studies 
of patients with chronic stable angina and acute coronary 
syndromes. The most common side effects of ranolazine 
consistently observed across these trials, in particular with 
higher doses, were constipation, dizziness, nausea, headache, 
asthenia, and peripheral edema.9,19,22
However, in the MARISA and CARISA trials, ranolazine 
was shown to increase the QTc, but without evidence of 
effect on QT dispersion or torsades de pointes.19,22 The larger 
MERLIN trial in patients with acute coronary syndrome 
confirmed the safety of ranolazine in a higher-risk ischemic 
population, showing no increase in torsades de pointes or 
other life-threatening arrhythmias.8 Syncope and postural 
hypotension have occurred in patients taking high doses (up 
to 2000 mg) of ranolazine.19,22 However, Holter monitoring 
during the first seven days of treatment in the MERLIN trial 
showed no evidence of arrhythmias associated with these 
side effects, and in fact revealed a reduction in both tachyar-
rhythmias and bradyarrhythmias in the ranolazine treatment 
arm.8 In general, most side effects from ranolazine treatment 
can be avoided by starting ranolazine with the lowest avail-
able dose and titrating the dose upward based on efficacy 
and tolerability.
Although the MERLIN-TIMI 36 trial does not support the 
use of ranolazine in patients with acute coronary syndrome 
to reduce subsequent death or myocardial infarction during 
follow-up, data from the trial confirmed the safety profile and 
tolerability of ranolazine and provided additional support for 
ranolazine as an antianginal drug in chronic angina. Ranola-
zine offers a second option for intensification of antianginal 
therapy in case first-line agents fail.7,13
Quality of life and economic impact
Despite advances in medical and interventional technologies, 
millions of people continue to experience angina symptoms. 
This not only translates into a dramatic worsening in their qual-
ity of life, but also represents a major public health problem.27,28 
Thus, patient-centered health status assessment that measures 
patient symptoms and function, as well as quality of life, is 
becoming an increasingly common outcome measure.27,28
Different health status/quality of life indicators have 
been used in recent studies of ranolazine,7,9 among them, 
the Seattle Angina Questionnaire, the Rose dyspnea scale, 
the Medical Outcomes Study 12-item Short Form (SF)-12, 
and the EuroQol-5D questionnaire.28 The Seattle Angina 
Questionnaire surveys patients on 19 items that measure five 
clinically important dimensions about health in patients with 
coronary artery disease, ie, angina frequency, angina   stability, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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physical limitations, treatment satisfaction, and disease 
perception/quality of life. The Rose dyspnea scale has four 
items to assess the level of a patient’s dyspnea with common 
activities. The SF-12 is used to assess general health status 
using the physical and mental components of a larger scale 
called the SF-36. Finally, the EuroQol-5D is a questionnaire 
with five items assessing mobility, self-care, usual activities, 
pain and discomfort, and anxiety/depression.28
Using data from the MERLIN trial, Arnold et al demon-
strated that compared with patients without angina, patients 
with daily angina had at least a two-fold increase in resource 
utilization, with an incremental cost of $4000 after eight 
months of follow-up.27
Secondary analyses from the same trial showed that overall 
there was only a small difference in quality of life between 
patients treated and not treated with ranolazine, and the 
greatest benefits of this medication were observed for angina 
frequency, overall quality of life, and treatment satisfaction on 
the Seattle Angina Questionnaire among those who had angina 
prior to the acute coronary syndrome event. Smaller benefits 
were observed in the SF-12 physical and mental component 
scores, Rose dyspnea score, and EuroQol-5D measures.28
In another study, a graded relationship was observed 
between higher angina frequency and health care costs, with 
costs more than twice as high among patients with daily 
angina compared with those without angina. No   differences 
in overall medication costs were observed between the angina 
frequency groups, perhaps because patients with higher 
angina frequency used more antianginal medications than 
statins and clopidogrel.27
Conclusion
The main goals of treatment of stable angina pectoris are 
to improve quality of life by reducing the severity and/or 
frequency of symptoms, to increase functional capacity, and 
to improve prognosis. Ranolazine has been shown to be a 
reasonable and safe option for patients who have refractory 
ischemic symptoms despite the use of usual medications for 
treatment of angina symptoms, and also provides slightly 
improved quality of life.
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